Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today announced the completion of patient enrollment and initial dosing across all cohorts in its...